Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

CN Bio enhances hepatotoxicity testing to improve drug safety, reducing the risk of costly clinical trial failures.

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

The data analysis is led by a team from the Michigan Kidney Translational Medicine Center at the University of Michigan. Some Endothelin Receptor Antagonists (ERAs) have caused elevations of ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Subsequently, its potential protective effect against hepatotoxicity induced by valproic acid (VPA) was investigated in Wistar rats, both as preventive and curative treatments. For this purpose, two ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

The hepatotoxicity of PM 2.5 Over the past 20 years, mortality due to air pollution has continued to rise, with over 6.7 million deaths reported in 2019 alone. In addition to the respiratory toxicity ...

Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix ® DILI assay kit: Human 24. Built upon CN Bio’s human-derived and highly ...

Even today, 30% of drug candidates fail in clinical trials, and 18% of these failures are attributed to hepatotoxicity concerns 1. Existing methods to assess human drug-induced liver injury (DILI ...